^
Association details:
| Biomarker: | BRAF V600 + LDH elevation + PD-L1 negative |
|---|---|
| Cancer: | Melanoma |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) + Cotellic (cobimetinib) (MEK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF V600 mutation-positive melanoma
Published date:
02/04/2022
Excerpt:
We report exploratory biomarker analyses to optimize targeting of patients who are more likely to benefit from triplet combination therapy....PFS benefit for atezolizumab versus control was greater in patients with high TMB [≥10 mutations/Mb; hazard ratio (HR) 0.73; 95% confidence interval (CI) 0.52-1.02; P = 0.067] versus low TMB (<10 mutations/Mb; HR 0.92; 95% CI 0.65-1.30; P = 0.64)...In patients with elevated LDH, PFS benefit for atezolizumab versus control was greater in the PD-L1- subgroup (HR 0.53; 95% CI 0.29-0.95; P = 0.032) than in the PD-L1+ subgroup (HR 1.16; 95% CI 0.75-1.80; P = 0.51).
DOI:
10.1016/j.annonc.2022.01.076
Source:
Title:
Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study
Published date:
09/14/2020
Excerpt:
In pts with LDH ≤ULN at baseline, PFS and DOR benefit with A+V+C were greater for the PD-L1+ subgroup. Conversely, in pts with LDH >ULN, benefit with A+V+C was greater in the PD-L1– subgroup.
Trial ID:
